1133-P: Value of Dexcom CGM for Therapy Optimization and Glycemic Outcomes in Post-Hospital Discharge Type 2 Diabetes Patients

MARGARET A. CRAWFORD, CHRISTIAN HICKS, TERESA ZHOU, YING XU, HARSIMRAN SINGH, DANIEL R. CHERÑAVVSKY, CAMILLA LEVISTER, NIRALI SHAH, MADELEINE ROUVIERE, ABIGAIL TAMRU, LEAH KAPLAN, DAVID W. LAM, GRENYE O'MALLEY, CAROL J. LEVY; 1133-P: Value of Dexcom CGM for Therapy Optimization and Glycemic Outcomes in Post-Hospital Discharge Type 2 Diabetes Patients—An Exploratory Study. Diabetes 14 June 2024; 73 (Supplement_1): 1133–P. https://doi.org/10.2337/db24-1133-P

Download citation file:

Ris (Zotero)
Reference Manager
EasyBib
Bookends
Mendeley
Papers
EndNote
RefWorks
BibTex

toolbar search

Search Dropdown Menu

Advanced Search

Post-hospital discharge (PHD) can be a challenging time for health care providers (HCPs) and patients. We analyzed use of Dexcom G6 CGMs in PHD T2D patient management.

This study analyzed 30 days of PHD remote monitoring data for 28 T2D patients. Hospital discharge summaries and telehealth notes were analyzed for details around hospital stay, PHD outcomes, and patient-HCP interactions.

Study sample was categorized into 3 cohorts to reflect disease severity and risk of mortality during hospitalization- Group A (Organ Transplants), Group B (High Severity), Group C (Medium Severity) (Table). Overall, Group B was the youngest (median (IQR): 37 years (37,55)) vs. Groups A & C (54 (47,59) & 55 (50,57)), had the shortest hospital stay (3 days (2,5)) vs. Groups A & C (8 (8,10) & 11 (7,15)) and the shortest diabetes duration (7 years (1,20) vs. Groups A & C (15 (2,27) & 10 (6,17)). Group A had the most telehealth encounters (20 (9,21) vs. Groups B & C (12 (11,15) & 12 (10,13)). Telehealth encounter notes detailed HCP interactions with CGM data including response to Dexcom Follow alerts, insulin titration, and diabetes self-care coaching. Using CGM, groups A & B showed decreased mean glucose and frequency of severe hypo- and hyper-glycemic events over the study period (Table).

These early findings demonstrate the value of CGM to inform critical therapy adjustments for optimizing outcomes during PHD.

View largeDownload slide

Close modal

Disclosure

M.A. Crawford: Employee; Dexcom, Inc. C. Hicks: Employee; Dexcom, Inc. T. Zhou: None. Y. Xu: Employee; Dexcom, Inc. H. Singh: Employee; Dexcom, Inc. D.R. Cherñavvsky: None. C. Levister: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc. N. Shah: None. M. Rouviere: None. A. Tamru: None. L. Kaplan: None. D.W. Lam: Research Support; Renalytix. G. O'Malley: Research Support; Dexcom, Inc., Insulet Corporation, Abbott, Tandem Diabetes Care, Inc., MannKind Corporation. C.J. Levy: Research Support; Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; MannKind Corporation, T1D Exchange, Tandem Diabetes Care, Inc., Abbott, Insulet Corporation.

2024

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

11 Views

View Metrics

Email alerts

Article Activity Alert

Online Ahead of Print Alert

Latest Issue Alert

Close Modal

Most Read
Most Cited

MRI Metrics of Cerebral Endothelial Cell–Derived Exosomes for the Treatment of Cognitive Dysfunction Induced in Aging Rats Subjected to Type 2 Diabetes

Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel

713-P: Is There a Correct Time to Measure Fasting Blood Sugar in Persons with Type 2 Diabetes Melitus?

Elevated First-Trimester Neutrophil Count Is Closely Associated With the Development of Maternal Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes

Fasting-Induced Lipolysis and Hypothalamic Insulin Signaling Are Regulated by Neuronal Glucosylceramide Synthase

1133-P: Value of Dexcom CGM for Therapy Optimization and Glycemic Outcomes in Post-Hospital Discharge Type 2 Diabetes Patients—An Exploratory Study (2024)

Email alerts

References